Search Results
Sep 03, 2026, 00:02 ET Huawei Unveils Next-Gen Flagship Products at "Chase the Wild" Global Innovative Product Launch Event in Munich
feature is not intended for medical use. Results are for reference only, and should not be used as a basis for medical diagnosis, or treatment. [iii] The feature is not intended for medical use. Results are for reference only, and should not be used as a basis for medical diagnosis, or treatment.
More news about: Huawei
Sep 02, 2026, 20:30 ET Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
this progress is Rentosertib (ISM001-055), the world's first drug candidate discovered and developed using generative AI, which has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF).About Insilico MedicineInsilico Medicine is a pioneering global biotechnology
More news about: Insilico Medicine
Sep 02, 2026, 20:30 ET Scienjoy Holding Corporation to Acquire 29.9% Stake in Chinese Higher Education Service Provider Leader Education Limited
results of its due diligence of Leader Education and its subsidiaries; (ii) the absence of any material breach of warranties in the SPA by Shuren; (iii) all necessary waivers, consents, and/or notifications having been obtained; (iv) the continued listing of Leader Education's ordinary shares on the
More news about: Scienjoy Holding Corporation
Sep 02, 2026, 19:40 ET HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims & Hers Class Action Lawsuit
submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them"; (iii) the foregoing conduct subjected Hims & Hers to regulatory scrutiny; (iv) as a result of the foregoing, Hims & Hers was reasonably likely to
More news about: Robbins Geller Rudman & Dowd LLP
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
significant and clinically meaningful improvement over pembrolizumab. HARMONi-2 is a randomized, double-blind, multicenter, registrational Phase III trial evaluating ivonescimab, Akeso's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as first-line treatment for patients with locally
More news about: Akeso, Inc.
Sep 02, 2026, 17:00 ET Prologis Declares Quarterly Dividend
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Sep 02, 2026, 16:05 ET Petco Reports Second Quarter 2026 Results
from multi-channel retailers, mass and grocery retailers, and e-Commerce providers); (ii) reduced consumer demand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract and retain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments;
More news about: Petco - Investor Relations
Sep 02, 2026, 14:00 ET Greenberg Traurig Represents JATT III Acquisition Corp on Nasdaq IPO
Greenberg Traurig, P.A. represented JATT III Acquisition Corp (the Company) in the closing of its initial public offering of 6.9 million ordinary shares at a price of $10 per share Aug. 27, including
More news about: Greenberg Traurig, LLP
Sep 02, 2026, 13:15 ET Aevex Corp. (AVEX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
significant portion of its Aevex holdings in the SPO, and the entirety of the SPO's net proceeds went to Madison, with Aevex earning zero from the SPO; (iii) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Sep 02, 2026, 13:00 ET Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.Contact Us To Participate or Learn More:
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Sep 02, 2026, 11:17 ET Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders
captured as liabilities in the valuations and trading multiples of U.S. Cannabis MSOs.The reclassification of medical cannabis from Schedule I to III on April 23, 2026 has removed the 280E tax treatment and ceased future accruals of the liability. The rescheduling of adult use cannabis is currently
More news about: Curaleaf Holdings, Inc.
Sep 02, 2026, 10:43 ET Banco ABC Brasil abre vagas em áreas de negócios, tecnologia e operações em diferentes regiões do país
e Imobiliárias Sr.Auxiliar Administrativo de Gestão de Garantias - afirmativa para pessoas com deficiênciaGerente de Relacionamento Corporate III (Recife)Jovem Aprendiz em Crédito Large Corporate (São Paulo, híbrido)Pessoa Auxiliar Administrativo Backoffice - afirmativa para pessoas
More news about: Banco ABC Brasil
Sep 02, 2026, 10:31 ET Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
limited or no approved targeted treatment options and has demonstrated positive outcomes across several Phase II and Phase III studies. Priovant is also assessing brepocitinib in a Phase III trial for non-infectious uveitis (NIU), with topline results anticipated in the second half of 2026.The anticipated
More news about: DelveInsight Business Research, LLP
Sep 02, 2026, 10:11 ET REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026
Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly
More news about: Levi & Korsinsky, LLP
Sep 02, 2026, 10:05 ET Southwest Airlines' First-Ever Lounges to Debut in Austin, Baltimore, Honolulu, and Nashville; with at Least Seven More Planned
systems and infrastructure to support its operations and initiatives, including with respect to revenue management and assigned and premium seating; (iii) consumer behavior and response with respect to Southwest's new commercial products and policies; (iv) the impact of fuel price changes,
More news about: Southwest Airlines Co.
Sep 02, 2026, 08:30 ET Tom Lee's Fundstrat Capital Completes August 2026 Rebalance For All Granny Shots ETFs
Capital, LLC is investment sub-adviser to the Granny Shots ETF suite. Tidal Investments LLC is investment adviser. The funds are series of Tidal Trust III and are distributed by Foreside Fund Services, LLC.Chief Investment Officer: Thomas "Tom" LeeETF Suite: GRNY, GRNI, GRNJ (NYSE Arca)Total
More news about: Fundstrat Capital
Sep 02, 2026, 08:12 ET Calumet Provides Update After Latest U.S. EPA Small Refinery Exemption Decision
the statements regarding (i) demand for finished products in markets we serve, (ii) our expectation regarding our business outlook and cash flows and (iii) our expectation that certain RINs will be removed from our balance sheet as a result of the EPA's recent SRE decisions. These forward-looking statements
More news about: Calumet, Inc.
Sep 02, 2026, 08:00 ET PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen
Sept. 2, 2026 /CNW/ -- PixCell Medical today announced its expansion into the Canadian market following the receipt of a Health Canada Class III Medical Device License for its HemoScreen™ point-of-care hematology analyzer and a new distribution partnership with Inter Medico. Building on the company's
More news about: PixCell Medical
Sep 02, 2026, 08:00 ET PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen
2, 2026 /PRNewswire/ -- PixCell Medical today announced its expansion into the Canadian market following the receipt of a Health Canada Class III Medical Device License for its HemoScreen™ point-of-care hematology analyzer and a new distribution partnership with Inter Medico. Building on the company's
More news about: PixCell Medical
Sep 02, 2026, 06:10 ET 캐나다 왕립 조폐국, 순금 및 순은 수집용 주화로 의회도서관 150주년 기념
뒤덮인 절벽을 선보인다. 스크롤 배너 위쪽에는 펼쳐진 책이 '1876'과 '2026'이라는 날짜를 표시하며 도서관의 150주년을 강조한다.이 두 주화 모두 앞면에는 캐나다 예술가 스티븐 로사티(Steven Rosati)가 제작한 찰스 3세(Charles III) 국왕의 초상이 새겨져 있다.화폐국은 이러한 역사적인 기념품들과 더불어 다음과 같은 여러 신규 수집용 주화를 출시한다.2026년 20달러 순은 주화 – 캐나다 국립 발레단(National Ballet of Canada)
More news about: Royal Canadian Mint (RCM)
Sep 02, 2026, 05:00 ET Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical study of 177Lu-NYM032 in China. 177Lu-NYM032 is a novel investigational PSMA-targeted, small-molecule therapeutic radiopharmaceutical
More news about: Norroy Bioscience Co., Ltd.
Sep 02, 2026, 05:00 ET Yatsen Announces Second Quarter 2026 Financial Results
income (loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions, (iii) revaluation of investments on the share of equity method investments, (iv) impairment of goodwill, (v) impairment of investments and (vi) tax effects
More news about: Yatsen Holding Limited
Sep 02, 2026, 04:10 ET TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM's incentive program
special rights and are negotiable instruments, (ii) give the right to dividends and other rights in relation to TORM as of the date of issuance and (iii) are expected to be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.After the capital increase, TORM's share
More news about: Torm PLC
Sep 02, 2026, 01:40 ET Bitmine Immersion Technologies (BMNR) Mengumumkan Kepemilikan ETH Mencapai 5,90 Juta Token, serta Total Kepemilikan Kripto dan Kas Sebesar $15,6 Miliar
Bitmine terus mendapat dukungan dari kelompok investor institusional terkemuka, termasuk Cathie Wood dari ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital, serta investor perorangan Thomas "Tom" Lee, untuk mendukung target Bitmine mengakuisisi 5% ETH
More news about: Bitmine Immersion Technologies, Inc.
Sep 02, 2026, 01:31 ET Este comunicado de imprensa contém declarações que constituem "declarações prospectivas" de acordo com a Lei de Reforma de Litígios de Valores Mobiliários Privados de 1995, conforme alterada.
continua contando com o apoio de um grupo de investidores institucionais de destaque, incluindo Cathie Wood da ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e o investidor individual Thomas "Tom" Lee, para viabilizar sua meta de adquirir 5% do ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.